Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Clerkin C[original query] |
---|
Preventing and managing chronic disease through implementation science: Editor's introduction to the supplemental issue
Smith JD , Naoom SF , Saldana L , Shantharam S , Smith TA , Kohr JM . Prev Sci 2023 People living with cardiovascular disease and other chronic conditions had a greater risk of complications and death during the COVID-19 pandemic (Abbasi, 2022; Clerkin et al., 2020; Vosko et al., 2023; Xie et al., 2022). Like many other health conditions, chronic diseases disproportionately affect people from minority groups and people with lower incomes (Caraballo et al., 2022; Crook & Peters, 2008). These health disparities were exacerbated by the COVID-19 disease and the effects of pandemic response measures on preventive healthcare in the USA (Andraska et al., 2021; Boehmer et al., 2022; Lopez et al., 2021). Amid the unprecedented public health crisis of COVID-19, there were many opportunities for prevention and for implementation scientists to create and test innovative solutions to mitigate these effects (Wensing et al., 2020). | | Implementation science has emerged as a potential solution to the failure to translate evidence from research into effective practice (Eccles & Mittman, 2006) and policy evident in many fields. Implementation science in health is the study of methods to promote the adoption and integration of evidence-based practices, interventions, and policies into routine healthcare and public health settings to improve our impact on population health (National Institutes of Health, 2022). The field seeks to understand the approaches that work best to translate research to real-world systems of care and further apply and adapt these approaches in different contexts and settings to improve public health. Implementation science, thus, could help maximize reach and impact of interventions for populations with chronic diseases. |
Evaluating early case capture of pediatric cancers in seven central cancer registries in the United States, 2013
Puckett M , Neri A , Rohan E , Clerkin C , Underwood J M , Ryerson A B , Stewart S L . Public Health Rep 2016 131 (1) 126-136 OBJECTIVE: Cancer is the second-leading cause of death in children, but incidence data are not available until two years after diagnosis, thereby delaying data dissemination and research. An early case capture (ECC) surveillance program was piloted in seven state cancer registries to register pediatric cancer cases within 30 days of diagnosis. We sought to determine the quality of ECC data and understand pilot implementation. METHODS: We used quantitative and qualitative methods to evaluate ECC. We assessed data quality by comparing demographic and clinical characteristics from the initial ECC submission to a resubmission of ECC pilot data and to the most recent year of routinely collected cancer data for each state individually and in aggregate. We conducted telephone focus groups with registry staff to determine ECC practices and difficulties in August and September 2013. Interviews were recorded, transcribed, and coded to identify themes. RESULTS: Comparing ECC initial submissions with submissions for all states, ECC data were nationally representative for age (9.7 vs. 9.9 years) and sex (673 of 1,324 [50.9%] vs. 42,609 of 80,547 [52.9%] male cases), but not for primary site (472 of 1,324 [35.7%] vs. 27,547 of 80,547 [34.2%] leukemia/lymphoma cases), behavior (1,219 of 1,324 [92.1%] vs. 71,525 of 80,547 [88.8%] malignant cases), race/ethnicity (781 of 1,324 [59.0%] vs. 64,518 of 80,547 [80.1%] white cases), or diagnostic confirmation (1,233 of 1,324 [93.2%] vs. 73,217 of 80,547 [90.9%] microscopically confirmed cases). When comparing initial ECC data with resubmission data, differences were seen in race/ethnicity (808 of 1,324 [61.1%] vs. 1,425 of 1,921 [74.2%] white cases), primary site (475 of 1,324 [35.9%] vs. 670 of 1,921 [34.9%] leukemia/lymphoma cases), and behavior (1,215 of 1,324 [91.8%] vs. 1,717 of 1,921 [89.4%] malignant cases). Common themes from focus group analysis included implementation challenges and facilitators, benefits of ECC, and utility of ECC data. CONCLUSIONS: ECC provided data rapidly and reflected national data overall with differences in several data elements. ECC also expanded cancer report¬ing infrastructure and increased data completeness and timeliness. Although challenges related to timeliness and increased work burden remain, indica¬tions suggest that researchers may reliably use these data for pediatric cancer studies. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure